Status:
COMPLETED
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
Eligibility Criteria
Inclusion
- Cytokine refractory metastatic renal cell carcinoma with clear cell component
- Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy
- Prior nephrectomy
Exclusion
- Prior treatment with any systemic therapy other than 1 cytokine therapy
- History of or known brain metastases
- Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00077974
Start Date
February 1 2004
End Date
September 1 2008
Last Update
October 13 2010
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Duarte, California, United States, 91010-3000
2
Pfizer Investigational Site
Pasadena, California, United States, 91105
3
Pfizer Investigational Site
San Francisco, California, United States, 94115
4
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114